drugset / Trial / NCT00496093
Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)
NaSingle-groupOpen-labelPrevention
Summary
To describe the safety, tolerability and immunogenicity of pneumovax 23 (V110) in healthy adults in India.
Timeline
- Start
- 2005-10
- Primary completion
- 2006-01
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pneumococcal Vaccine, Polyvalent (23-valent) | Vaccine | 0.5 ml | Intramuscular |